Granules India credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,3381,3381,2861,2231,059
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
389389689837746
0.26×0.26×0.35×0.38×0.37×
0.08×0.08×0.19×0.26×0.26×
1.13×1.13×1.36×1.43×1.16×
0.30×0.33×0.73×0.98×0.82×
7.77×7.77×6.97×6.13×13.04×
20.8%20.8%25.7%27.5%27.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹840.45

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,826 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1,058.61,223.21,285.81,338.11,338.1
Net Debt745.8836.8689.4389.1389.1
Total Debt/Equity0.370.380.350.260.26
Net Debt/Equity0.260.260.190.080.08
Total Debt/EBITDA1.161.431.361.131.13
Net Debt/EBITDA0.820.980.730.330.30
Interest Coverage (EBIT/Interest)13.046.136.977.777.77
Total Debt/Total Capital %27.1927.5025.7120.8320.83
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.